CAIHL read · Jun 12, 2026

← Back to Jun 12, 2026 scan

AI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data finds

What CAIHL does

Critical AI Health Literacy (CAIHL) is an analytical lens — Hugo Campos and Liz Salmi's 2025 National Academy of Medicine commentary, "Critical AI Health Literacy as Liberation Technology." It applies Paulo Freire's theory of critical literacy to health AI.

The central question CAIHL asks is whose interests does this AI actually serve? Four dimensions answer it: who is the primary user, where is it hosted, whose interests does it advance, and does it expand or constrain patient agency.

This deep-read separates the four dimensions on a single item from the day's scan, so you can see the specific structural shape of the AI in question — not just the bucket it landed in.

How this item reads through CAIHL

Primary user

mixed

Both patients and clinicians interact directly with this AI.

Hosting

government

Hosted or controlled by a government agency or program.

Interests

mixed

Multiple stakeholder interests in tension; the alignment is not stable.

Agency

constraining

Channels patients toward predetermined pathways or substitutes for patient capabilities.

One-sentence synthesis

Federal agency AI deployment outpacing oversight architecture; constraining agency where the deployment outruns the disclosure.

How this item appeared in the daily scan

Editor's note: Federal-agency AI adoption running at 148% YoY at the FDA is the deployment trajectory the AMA's just-adopted transparency policy is trying to match. Whichever side scales faster determines which side patients will be operating inside next year.

Summary: Fierce Healthcare: Bipartisan Policy Center analysis showing AI use across HHS surged in 2025 — FDA deployment jumped 148% year-over-year — with documentation of which agency sub-units expanded most aggressively.

Read the original source →

methodology

Limitations

CAIHL is a lens, not a verdict. The four dimensions are conditions of use — reassess them when a tool's business model, deployment context, or patient behavior changes. See the NAM commentary for the full framework.